secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2026-08-05T12:05:10+00:00
Accession:  0001193125-26-333912
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImageneBio Q2 2026 net loss $10.2M ($0.63/sh); cash $136.2M funds into Q1 2028
------------------------------------------------------------------------------

- Net loss of $10.2M ($0.63 loss per share) vs $10.7M ($4.46) in Q2 2025.
- Cash, equivalents and marketable securities $136.2M as of June 30, 2026.
- R&D expenses $6.7M (up from $5.7M); G&A expenses $5.1M (up from $1.7M) YoY.
- Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis on track; topline data expected Q4 2027.
- Appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel in July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/0001193125-26-333912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer